Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Misses Estimates By $0.04 EPS

Sana Biotechnology (NASDAQ:SANA) released its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04), Zacks reports.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA traded up $0.25 during mid-day trading on Friday, hitting $4.91. 2,261,241 shares of the company’s stock traded hands, compared to its average volume of 1,825,041. Sana Biotechnology has a 1 year low of $2.74 and a 1 year high of $12.00. The company’s 50-day moving average is $5.90 and its two-hundred day moving average is $7.53. The company has a market capitalization of $1.09 billion, a P/E ratio of -3.21 and a beta of 1.45.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 target price on the stock. Citigroup boosted their target price on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday. Finally, HC Wainwright cut their price target on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.